The pharmaceutical manufacturer Amneal emphasizes the strong commercial recording for Parkinson's medication, but the results of the first Q1 are mixed – Amneal Pharmaceuticals (Nasdaq: Amrx)

AMNEAL pharmaceuticals Inc. Amrx reported in the first quarter of 2025, adapted EPS of 21 cents, compared to 14 cents a year ago and the consensus of 15 cents.

The company reported sales of $ 695.42 million, an increase of 5% compared to the previous year, which was lacking in the consensus of $ 715.49 million.

Affordable medication '(previously generic') rose by 6%, which is due to the strong performance of its complex product portfolio and the new product launches.

Sales with special net commitments increased by 3%, which is due to important branded products, including CREXONT and unithroid.

Avkare sales sales turn 6%, which is due to the growth of the government identification channel.

Read also: The combination of amneals shows improved sleep quality in Parkinson's disease patients

The company's net result was 12 million US dollars in the first quarter of 2025. In the first quarter of 2024, he reported a net loss of $ 92 million, which corresponded to a legal comparison fee of 94 million US dollars.

The adjusted EBITDA was 170 million US dollars, an increase of 12% compared to the first quarter of 2024, which reflects the strong sales performance, a higher gross margin and operating costs.

Directions: Amneal confirms in 2025 income instructions of $ 3 billion $ 3.1 billion and adjusted EPS of $ 65-70 cents. Compare this with the consensus of 3.03 billion US dollars or 68 cents.

The company expects 650 million US dollars -$ 675 million in 2025. It also has an operational cash flow of up to 285 million US dollars and investment expenditure of approximately 100 million US dollars.

In March, the US Food and Drug Administration (FDA) accepted two proposed Denosumab Biosimilars, the Prolia and XGEVA.

The FDA assigned a destination date in the fourth quarter of 2025. Amneal is currently commercializing three biosimilars in the United States. In addition, three other biosimilars are under development. This positions itself to have a portfolio of six biosimilars in eight product presentations by 2027.

Price action: The AMRX share dropped by 1.16% at 7.65 USD at the last check on Friday.

Read next: